Can vitreous reflux affect the short-term treatment response after intravitreal ranibizumab injection?

Basit Öğe Kaydı
dc.authorid0000-0003-4468-3985en_US
dc.authorid0000-0003-2544-3580en_US
dc.authorid0000-0001-5454-3113en_US
dc.contributor.authorUyar, Enes
dc.contributor.authorUlaş, Fatih
dc.contributor.authorAlkan, Yunus
dc.date.accessioned2021-06-23T19:55:16Z
dc.date.available2021-06-23T19:55:16Z
dc.date.issued2021
dc.departmentBAİBÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.description.abstractPurpose The aim of this study was to evaluate the effect of vitreous reflux (VR) on the short-term effect of intravitreal ranibizumab injection. Materials and Methods The study included 181 eyes of 81 age-related macular degeneration (AMD) and 100 diabetic macular edema (DME) patients. Treatment response was evaluated by measuring central macular thickness (CMT) as well as 1 mm and 3 mm central macular thicknesses (MT1 and MT3). Patients were grouped as; Group 1: no VR, Group 2: <3 mm VR, and Group 3: >3 mm VR according to conjunctival bleb diameters. The data were analyzed using variance, correlation and regression analyses. Results In AMD patients, reduction of CMT values following the treatment were 88.3 +/- 110.6 mu m in Group 1, 85.6 +/- 158.7 mu m in Group 2, and 93.1 +/- 92.2 mu m in Group 3. Likewise, in DME patients, it was 82.4 +/- 88.4 mu m, 72.9 +/- 109.9 mu m, and 73.7 +/- 113.7 mu m, respectively. Reduction of MT1 values after the treatment were 47.4 +/- 72.6 mu m, 36.0 +/- 131.9 mu m, and 36.7 +/- 114.4 mu m in AMD patients, and 33.3 +/- 72.5 mu m, 36.6 +/- 90.2 mu m, and 46.9 +/- 83.4 mu m in DME patients. In all comparisons among groups of VR, macular thickness (MT) change did not exhibit significant difference following an intravitreal ranibizumab treatment (p> .05). Conclusion We found that the increase in VR amount did not adversely affect the decrease in MT after intravitreal ranibizumab treatment in AMD and DME patients.en_US
dc.identifier.doi10.1080/02713683.2020.1789664
dc.identifier.endpage254en_US
dc.identifier.issn0271-3683
dc.identifier.issn1460-2202
dc.identifier.issue2en_US
dc.identifier.pmid32635750en_US
dc.identifier.scopus2-s2.0-85087649349en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage248en_US
dc.identifier.urihttps://doi.org/10.1080/02713683.2020.1789664
dc.identifier.urihttps://hdl.handle.net/20.500.12491/10768
dc.identifier.volume46en_US
dc.identifier.wosWOS:000547658000001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorUlaş, Fatih
dc.institutionauthorAlkan, Yunus
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofCurrent Eye Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAge-related Macular Degenerationen_US
dc.subjectDiabetic Macular Edemaen_US
dc.subjectIntravitreal Ranibizumaben_US
dc.subjectMacular Thicknessen_US
dc.subjectTreatment Responseen_US
dc.subjectVitreous Refluxen_US
dc.titleCan vitreous reflux affect the short-term treatment response after intravitreal ranibizumab injection?en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
enes-uyar.pdf
Boyut:
4.87 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu